Company Overview
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -46.24% |
| 6 Months: | -87.02% |
| 3 Months: | -77.99% |
| 1 Month: | -22.25% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)31.76 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 88.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CNTX Context Therapeutics Inc. PHARMA | 0.38 | -0.79 | $34.91M | 0.00% | -65.65% | -76.14% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | - | - | -651.06K | -840.32K | -5.03M | -1.57M | -3.44M | -4.01M | -4.05M | -6.67M | -5.29M | -6.18M | -3.82M | -3.09M | -18.70M | -5.53M | -9.76M | -10.61M | -9.34M | -14.97M |
| Net Income | 826.48K | 7.48M | -876.24K | -892.05K | -5.03M | -1.44M | -3.44M | -3.99M | -3.85M | -6.31M | -5.01M | -5.87M | -3.67M | -2.25M | -17.46M | -4.58M | -8.83M | -9.69M | -8.68M | -14.56M |
| Diluted EPS | - | - | -2.52 | -2.55 | -14.18 | -4.00 | -0.22 | -0.25 | -0.24 | -0.40 | -0.31 | -0.37 | -0.23 | -0.04 | -0.22 | -0.05 | -0.09 | -0.10 | -0.09 | -0.15 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Income | -2.57M | -10.53M | -15.38M | -25.07M | -29.92M | -39.70M |
| Net Income | 6.64M | -10.46M | -14.84M | -23.96M | -26.73M | -36.12M |
| Diluted EPS | -3.96 | -3.69 | -0.93 | -1.50 | -0.46 | -0.38 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 467.34K | 51.31M | 37.97M | 16.06M | 98.13M | 68.49M |
| Total Equity | -23.96M | -16.92M | 48.27M | 34.76M | 11.87M | 95.27M | 60.47M |
| Cash & Equivalents | - | 290.67K | 49.64M | 35.50M | 14.45M | 94.43M | 66.00M |
| Total Liabilities | - | 9.62M | 3.03M | 3.21M | 4.19M | 2.86M | 8.02M |
| Current Liabilities | - | 9.55M | 3.03M | 3.21M | 4.19M | 2.75M | 8.02M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -1.03M | -8.80M | -13.55M | -21.05M | -14.56M | -26.39M |
| Investing Cash Flow | 0 | -250.00K | -536.84K | 0 | -14.76M | -2.03M |
| Financing Cash Flow | 1.15M | 58.39M | -102.07K | 0 | 109.29M | -15.27K |
| Capital Expenditure | - | -0 | -36.84K | -0 | -7.32K | -33.95K |
| Free Cash Flow | - | -8.80M | -13.59M | -21.05M | -14.56M | -26.42M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | -39.3% | -21.7% | -42.7% | -201.9% | -28.1% | -59.7% |
| ROCE % | 28.3% | -21.8% | -44.3% | -211.2% | -31.4% | -65.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Deep Track Capital, Lp | 8.08% | 7.42M | $2.73M |
| 2 | Nextech Invest, Ltd. | 8.08% | 7.42M | $2.73M |
| 3 | Soleus Capital Management, L.P. | 7.69% | 7.06M | $2.60M |
| 4 | Blackrock Inc. | 6.71% | 6.17M | $2.27M |
| 5 | Avidity Partners Management, LP | 5.44% | 5.00M | $1.84M |
| 6 | Franklin Resources, Inc. | 4.14% | 3.80M | $1.40M |
| 7 | Vanguard Capital Management LLC | 3.74% | 3.43M | $1.26M |
| 8 | Octagon Capital Advisors LP | 3.32% | 3.05M | $1.12M |
| 9 | Blue Owl Capital Holdings LP | 3.19% | 2.93M | $1.08M |
| 10 | TCG Crossover Management, LLC | 2.92% | 2.68M | $987.50K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CNTX
CNTX Hits Worst Day In History After Ovarian Cancer Trial Data — But Analysts See Buying Opportunity In Dip - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi9wFBVV95cUxOZE1xUmI1N0ZzbVBpOHhGTm5GaG16a3g3YjFpOUlYV2JnNmJyblVfRS1VZ0FoeEF3R0xpc2hiZjU0ejRWSHJGSk9aN3A2X0dKeTl2d3BfS0p3d016N2k5a3pvTUVjYjM1anlSbV8zbFhJUTNJdzVwd2VBYTdySU9wR1FqWkhXZDNqMHRtb0…
Maxim Says Context Therapeutics (CNTX)’s Share Pullback Is an Overreaction; Remains Bullish - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxOQkhFazJGSkI0Rm5wbmduVE5OOUtWSjM0bVktakFmM3lYZTJzRTh0MkZrVFF6b0pqcktxd1ZkRFZTQW1aMDJoMUtRWS1MN2p5T0xrQXJUbGozWGxaZzBjV2x5RVZSZnc0djZna0RQeFNrN1oyeWlwVHo5c28wUTdScVBEUzltS1lpUjNfcE…
Context Therapeutics joins Russell 2000 and 3000 indexes - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxOakVTUDBVeUU0YUdnUktOYl8zbThNSjc2d0tOMFo1ZXdJVXRIaElNSURjZHZCZzlRdkNBZnR5SnpwaTlrNXJUSFFaNVNFcW1MSnlaV0xWWURlLTM4Z3daWnRURXQtNE9vSnl2dnFuZE9hMU5qTnJtdXY4bjczdTN0WENxZVNINlFIbElQeH…
CNTX - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE5pVWFfSFBGbzVTM0ZXLXhVZWlnSE5vMVlTbDdQS2NrSlFQWEtDaVBpaXB1NmNlMGRMQU9oOU5DSlk3ZDZmUUE?oc=5" target="_blank">CNTX</a> <font color="#6f6f6f">Finviz</font>…
CNTX Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9QdTJjV0FzYVpPaTZxUE5OSXJFZnZpVFZubEt3TGUweXg5V2pTYWhzM1dUZFR0bm1VY25wMkFnbkZZdldQX2JUQ0lxbHdUYk5yNEloekZ6bE1JdVNiY1JWU21LYWttalI0bkFpNU1fVE5hVlZQX3E5c0ln?oc=5" target="_blank">CNT…
Can Context Therapeutics (NASDAQ:CNTX) Afford To Invest In Growth? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi6gFBVV95cUxNQnRVX1RiODFPT1BQWmw4dHQ0REx6TmtWYzRCUjJSMDE2TWlBNTdEVHZDT3BGX3I0TURvYlRBVUdqQ3VZNEdMNzNTYzh6dXl6Z0RzYmFVY1hJbDJEbW5DNnhWUGlZU0E2NTZfVDMwd1RjbDJUZnJqbVNJUzBrV0x4Z25xb2xJMWRFZ3JBNT…
CNTX — Frequently Asked Questions
What is the current share price of Context Therapeutics Inc. (CNTX)?
As of 2026-09-19 21:16 PDT, Context Therapeutics Inc. (CNTX) trades at $0.38 on NasdaqCM. Its 52-week range is $0.36 to $3.36.
What is the market capitalisation of CNTX?
Context Therapeutics Inc. (CNTX) has a market capitalisation of $34.91M on NasdaqCM.
What is the P/E ratio of CNTX?
CNTX trades at a trailing price-to-earnings (P/E) ratio of -0.79. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.89.
What is the return on equity (ROE) of CNTX?
CNTX has a return on equity (ROE) of -76.14%. Its return on capital employed (ROCE) is -65.65%.
Is CNTX a good stock to buy?
This page provides a data-driven analysis of Context Therapeutics Inc. (CNTX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.